共 11 条
[1]
Siegel R., Naishadham D., Jemal A., Cancer statistics, 2013, CA Cancer J Clin, 63, 1, pp. 11-30, (2013)
[2]
Silva N.N., Eng C., Management of refractory metastatic anal squamous cell carcinoma following disease progression on traditional chemoradiation therapy, J Adv Pract Oncol, 3, pp. 161-169, (2012)
[3]
Rivera F., Garcia-Castano A., Vega N., Et al., Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial, Expert Rev Anticancer Ther, 9, 10, pp. 1421-1428, (2009)
[4]
Pirker R., Pereira J.R., Szczesna A., Et al., Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomized phase III trial, Lancet, 373, 9674, pp. 1525-1531, (2009)
[5]
Zampino M.G., Magni E., Sonzogni A., Et al., K-ras status in squamous cell anal carcinoma (SCC): it’s time for target-oriented treatment?, Cancer Chemother Pharmacol, 65, 1, pp. 197-199, (2009)
[6]
Le L.H., Chetty R., Moore M.J., Epidermal growth factor receptor expression in anal canal carcinoma, Am J Clin Pathol, 124, 1, pp. 20-23, (2005)
[7]
Klimant E., Markman M., Management of two cases of recurrent anal carcinoma, Case Rep Oncol, 6, 3, pp. 456-461, (2013)
[8]
Barmettler H., Komminoth P., Schmid M., Et al., Efficacy of cetuximab in combination with FOLFIRI in a patient with KRAS-wild type metastatic anal cancer, Case Rep Oncol, 5, 2, pp. 428-433, (2012)
[9]
Phan L.K., Hoff P.M., Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: a report of a case, Dis Colon Rectum, 50, 3, pp. 395-398, (2007)
[10]
Saif M.W., Kontny E., Syrigos K.N., The role of EGFR inhibitors in the treatment of metastatic anal canal carcinoma: a case series, J Oncol, (2011)